

Journal of Visualized Experiments

Spore Adsorption as a Nonrecombinant Display System for Enzymes and Antigens

--Manuscript Draft--

Article Type:	Invited Methods Article - JoVE Produced Video
Manuscript Number:	JoVE59102R2
Full Title:	Spore Adsorption as a Nonrecombinant Display System for Enzymes and Antigens
Keywords:	mucosal delivery, vaccines, recyclable enzymes, biocatalyst, spore formers, display platform
Corresponding Author:	Ezio Ricca Universita degli Studi di Napoli Federico II Naples, Naples ITALY
Corresponding Author's Institution:	Universita degli Studi di Napoli Federico II
Corresponding Author E-Mail:	ericca@unina.it
Order of Authors:	Rachele Isticato Ezio Ricca Loredana Baccigalupi
Additional Information:	
Question	Response
Please indicate whether this article will be Standard Access or Open Access.	Standard Access (US\$2,400)
Please indicate the city, state/province, and country where this article will be filmed . Please do not use abbreviations.	Naples, Italy



UNIVERSITÀ DEGLI STUDI DI NAPOLI FEDERICO II
Scuola Politecnica e delle Scienze di Base
Dipartimento di Biologia



Naples, November 8th, 2018

Dear Editor,

I would like to thank you and the Reviewers for your consideration of our manuscript and the comments aimed at improving it.

We are now submitting a revised version of the manuscript that takes into consideration all comments raised by you and the Reviewers. In this “revised version” all changes are marked in red and the essential steps of the protocol are highlighted in yellow.

A point-by-point response (rebuttal letter) to the reviewer’s comments has been provided.

We hope our manuscript is now suitable for publication on JOVE

Sincerely,

Ezio Ricca

TITLE:

Spore Adsorption as a Nonrecombinant Display System for Enzymes and Antigens

AUTHORS AND AFFILIATIONS:

Rachele Istatico¹, Ezio Ricca¹, Loredana Baccigalupi¹

¹Department of Biology, Federico II University, Naples, Italy

Corresponding author:

Ezio Ricca (ericca@unina.it)

Tel: +39-081-679036

Email addresses of co-authors:

Rachele Istatico (isticato@unina.it)

Loredana Baccigalupi (lorbacci@unina.it)

KEYWORDS:

Mucosal delivery, vaccines, recyclable enzymes, biocatalyst, spore formers, display platform

SUMMARY:

This protocol focuses on the use of bacterial spores as a “live” nanobiotechnological tool to adsorb heterologous molecules with various biological activities. The methods to measure the efficiency of adsorption are also shown.

ABSTRACT:

The bacterial spore is a metabolically quiescent cell, formed by a series of protective layers surrounding a dehydrated cytoplasm. This peculiar structure makes the spore extremely stable and resistant and has suggested the use of the spore as a platform to display heterologous molecules. So far, a variety of antigens and enzymes have been displayed on spores of *Bacillus subtilis* and of a few other species, initially by a recombinant approach and, then, by a simple and efficient nonrecombinant method. The nonrecombinant display system is based on the direct adsorption of heterologous molecules on the spore surface, avoiding the construction of recombinant strains and the release of genetically modified bacteria in the environment. Adsorbed molecules are stabilized and protected by the interaction with spores, which limits the rapid degradation of antigens and the loss of enzyme activity at unfavorable conditions. Once utilized, spore-adsorbed enzymes can be collected easily with a minimal reduction of activity and reused for additional reaction rounds. In this paper is shown how to adsorb model molecules to purified spores of *B. subtilis*, how to evaluate the efficiency of adsorption, and how to collect used spores to recycle them for new reactions.

INTRODUCTION:

Display systems are aimed at presenting biologically active molecules on the surface of microorganisms and finding applications in a variety of fields, from industrial to medical and environmental biotechnologies. In addition to phages^{1,2} and cells of various Gram-negative and -positive species³⁻⁷, bacterial spores have also been proposed as display systems by two approaches^{8,9}.

Because of its peculiar structure, namely a dehydrated cytoplasm surrounded by a series of protective layers¹⁰, the spore provides several advantages over phage- and cell-based display systems^{8,9}. A first advantage comes from the extreme robustness and stability of spores at conditions that would be deleterious to all other cells^{10,11}. Spore-displayed antigens and enzymes are stable after prolonged storage at room temperature¹² and protected from degradation at low pH and high temperatures¹³. A second advantage of spores is the safety of many spore-forming species. *B. subtilis*, *B. clausii*, *B. coagulans*, and several other species are used worldwide as probiotics and have been on the market for human or animal use for decades^{14,15}. This exceptional safety record is an obvious general requirement for a surface display system and is of particular relevance when the system is intended for human or animal use¹⁶. A third, important advantage of a spore-based display system is that it does not have limitations for the size of the molecule that has to be exposed. In phage-based systems, a large heterologous protein may affect the structure of the capsid, while in cell-based systems, it may affect the structure of the membrane or may limit/impair the membrane translocation step¹⁷. The protective layers surrounding the spore are composed of more than 70 different proteins¹⁰ and are flexible enough to accept large foreign proteins without any evident structural defect or functional impairment⁸. In addition, with both spore-based display systems, the membrane translocation of the heterologous protein is not required^{8,9}. Indeed, heterologous proteins are either produced in the mother cell cytoplasm and assembled on the spore that is forming in the same cytoplasm or adsorbed on the mature spore^{8,9}.

Spore display was initially obtained by developing a genetic system to engineer the spore surface¹⁸. This genetic system was based on i) the construction of a gene fusion between the gene coding for a spore coat protein (used as a carrier) and the gene coding for the protein to be displayed—the presence of the transcriptional and translational signals of the endogenous gene will control the expression of the fusion, and ii) integration of the chimeric gene on the *B. subtilis* chromosome to grant genetic stability. A variety of antigens and enzymes have been displayed by this recombinant approach, using various spore surface proteins as carriers and aiming at various potential applications, ranging from mucosal vaccine to biocatalyst, biosensor, bioremediation, or bioanalytical tool^{8,13}.

More recently, a different approach of spore display has been developed¹⁹. This second system is nonrecombinant and relies on the spontaneous and extremely tight adsorption of molecules on the spore surface⁹. Antigens^{19,20} and enzymes^{13,21} have been efficiently displayed and have revealed that this method is significantly more efficient than the recombinant one. This nonrecombinant approach allows the display of proteins in the native form²⁰ and can also be used with autoclaved, death spores¹⁹. The molecular mechanism of adsorption has not been fully clarified yet. The negative charge and the hydrophobicity of the spore have been proposed as properties relevant for the adsorption^{13,19,22}. Recently, it has been shown that a model protein, the red autofluorescent protein (mRFP) of the coral *Discosoma*, when adsorbed to the spore, was able to infiltrate through the surface layers localizing in the inner coat²³. If proved true for other proteins, the internal localization of the heterologous proteins could explain their increased stability when adsorbed to spores²³.

In a recent study, two enzymes catalyzing two successive steps of the xylan degradation pathway were independently displayed on spores of *B. subtilis* and, when incubated together, were able to perform both degradation steps²¹. Spores collected after the reaction were still active and able to continue the xylan degradation upon the addition of fresh substrate²¹. Even if a loss of about 15% of the final product

was observed in the second reaction²¹, the reusability of adsorbed enzymes for single, as well as multi-step, reactions is an additional important advantage of the spore display system.

Pan et al.²⁴ reported an additional approach to display heterologous proteins on the spore surface: heterologous proteins (an endoglucanase protein and a beta-galactosidase one) produced in the mother cell during sporulation were spontaneously encased in the forming spore coat, without the need of a carrier. This additional spore display system is a combination of the two approaches described so far. Indeed, it is recombinant since the heterologous proteins were engineered to be expressed in the mother cell during sporulation, while their assembly within the coat was spontaneous and, therefore, nonrecombinant²⁴. However, the efficiency of display of this additional approach remains to be tested and compared with the other two approaches by using the same heterologous proteins.

The present protocol excludes the processes of spore production and purification, which have been described extensively elsewhere²⁴. It includes the adsorption reaction, the evaluation of the efficiency of adsorption by dot-blotting and fluorescence microscopy, and the recycling of adsorbed enzymes for additional reaction rounds.

PROTOCOL:

1. Adsorption reaction

1.1. Incubate 2, 5, and 10 µg of mRFP with 2×10^9 of *B. subtilis* wild-type purified spores in 200 µL of binding buffer, 50 mM sodium citrate, pH 4.0 (16.7 mM sodium citrate dihydrate; 33.3 mM citric acid) for 1 h at 25 °C on a rocking shaker (Figure 1).

1.2. Centrifuge the binding mixtures (13,000 x g for 10 min) to fractionate pellets (P2, P5, and P10) and supernatants (S2, S5, and S10). Store the supernatants for the indirect evaluation of the efficiency of adsorption described in step 3.2.

1.3. Wash the pellets 2x with 200 µL of binding buffer and resuspend them in 100 µL of binding buffer and use it for the next analysis.

NOTE: The binding reaction preferentially occurs at a pH value lower than the isoelectric point of the protein; typically, 1.5 M phosphate-buffered saline (PBS), pH 4.0, or 50 mM sodium citrate, pH 4.0, are used.

2. Direct evaluation of the efficiency of adsorption

2.1. Extraction of surface proteins and western blot analysis

2.1.1. Take 50 µL of mRFP-adsorbed spores' resuspension (P2, P5, and P10 of step 1.3) and add 50 µL of 2x sodium dodecyl sulfate (SDS)-dithiothreitol (DTT) (0.1 M Tris-HCl, pH 6.8; 2% SDS; 0.1 M DTT) to solubilize surface spore proteins.

2.1.2. Use the free, purified mRFP and extracts of the same amounts of spores that are not adsorbed to the protein as positive and negative controls, respectively.

2.1.3. After 45 min of incubation at 65 °C, centrifuge (13,000 x *g* for 10 min) the mixtures and analyze 10 µL of the extracted proteins (supernatant) by western blot with the monoclonal anti-His antibody recognizing the His tag present at the N-terminal of mRFP (Figure 2A).

2.2. Fluorescent microscopy observations

NOTE: By using fluorescent heterologous proteins or performing an immunofluorescence analysis, it is possible to localize and quantify the adsorbed molecules by fluorescence microscopy.

2.2.1. Take 5 µL of the adsorbed spores' resuspension from step 1.3 and add 95 µL of 1x PBS, pH 4.0, to obtain ~1 x 10⁶ spores/µL.

2.2.2. Place 5 µL of suspension on a microscope slide, cover it with a coverslip previously treated with poly-L-lysine for 30 s, and observe it under a fluorescence microscope.

2.2.3. For each field, save the phase-contrast microscopy image and fluorescence microscopy image (Figure 2B).

NOTE: Alternatively, fluorescent spores can be analyzed by cytofluorimetry. Resuspend a total of 10⁶ spores adsorbed or not-adsorbed with the heterologous protein in 1 mL of 1x PBS, pH 4.0, and analyze the suspension using a flow cytometer (Figure 2C).

2.3. Data analysis using ImageJ

2.3.1. Open the fluorescence microscopy images with ImageJ software (<http://rsbweb.nih.gov/ij/>) and check to make sure all images are in the 8-bit format (Image | Type | 8-bit).

2.3.2. Adjust the contrast if necessary (Image | Adjust | Brightness Contrast) and verify that the scale of the image is PIXEL (Image | Set Scale).

2.3.3. From the Analyze menu, select **Set measurements**. Make sure to have **Area**, **Integrated Density**, and **Mean Gray Value** selected.

2.3.4. Draw a line around the spore of interest using any of the drawing/selection tools (i.e., circle, polygon, or freeform) (Figure 3).

2.3.5. Select **Measure** from the Analyze menu (or hit **cmd + M**). A popup box with a stack of values for this first spore appears (Figure 3).

2.3.6. Repeat these two steps for at least 50 other spores in the field of view chosen to be measured.

2.3.7. Select several regions without any spores (that have no fluorescence) and repeat the measurement; this will be the background.

NOTE: The size is not important. These corresponding background fluorescence values will be used to manually subtract the background.

2.3.8. Select all the data in the Results window and copy the results into a spreadsheet.

2.3.9. Calculate the mean of the **Integrated Density** and **Area** of the selected spores and of the background fluorescence values and use them to obtain the corrected total-per-cell fluorescence (CTCF) using the formula: $CTCF = \text{mean Integrated Density} - (\text{mean Area} \times \text{mean Background fluorescence})$.

NOTE: Alternatively, if all the spores appear well separated, it is possible to analyze all the spores of the image field using the function **Analyze Particles**, following ImageJ's instruction. To avoid that the software reads a specific fluorescence or spore aggregates, the dimension of particles has to be set at $\text{pixel}^2 = 50\text{--}200$ (**Figure 4**).

3. Indirect evaluation of the efficiency of adsorption

3.1. Prepare serial dilutions for the purified protein.

3.1.1. Prepare a first 1.5 mL tube containing 250 μL of purified mRFP at a final concentration of 0.5 ng/ μL , using the binding buffer. This volume is sufficient to load two lanes.

3.1.2. Perform six twofold serial dilutions of 250 μL (final volume) each, using the binding buffer.

3.2. Prepare twofold serial dilutions for the supernatant samples containing the unbound mRFP fraction of the adsorption reaction (S2, S5, and S10 from step 1.2).

3.2.1. Put 100 μL of each supernatant in a 1.5 mL tube and add 100 μL of binding buffer. Perform six twofold serial dilutions of 200 μL (final volume) each, using the binding buffer.

3.3. Cut a nitrocellulose membrane (0.45 μm cutoff), 9 cm x 10 cm in size, to cover the area of 5 (number of samples) x 6 (number of dilutions) dots. The membrane should not extend beyond the edge of the gasket of the dot blot apparatus.

3.4. Place the prewet membrane in the dot blot apparatus. Remove any air bubbles trapped between the membrane and the gasket. Cover the unused portion of the apparatus with tape or paraffin film to prevent air from moving through those wells.

3.5. Assemble the dot blot apparatus as described by the manufacturer.

3.6. If a vacuum is used during the assembling, rehydrate the membrane with 100 μL of 1x PBS per well to ensure the uniform binding of the antigen and prevent halos or a weak detection signal.

3.7. Gently remove the buffer from the wells by vacuum. As soon as the buffer solution drains from all the wells, stop the vacuum pump and disconnect it.

3.8. Load the standard in the two most external lanes and the samples in the middle (**Figure 5**). Fill the appropriate wells with 100 μ L of each dilution. The same volume used for each well should ensure a homogeneous filtration of all sample wells.

3.9. Turn on the vacuum pump for 2 min, stop it, and then, allow the sample to filter through the membrane by gravity flow.

3.10. Wash all the wells with 100 μ L of 1x PBS and let the vacuum pump run for another 5 min after the washing buffer has been completely drained from the apparatus.

3.11. With the vacuum on, loosen the screws, and carefully open the dot blot apparatus.

3.12. Turn off the vacuum, take the membrane, and process it following a western blot protocol.

3.13. Perform a densitometric analysis of the filter, using appropriate software, such as ImageJ.

3.13.1. Measure the integrated density of each dot by outlining them with a circle of the same area and using the **Analyze/Measure** command.

3.13.2. Make a background correction of the image, drawing a circle in an empty area and measuring its integrated density or using the **Process/Subtract Background** command.

3.13.3. Correlate the integrated density of the standard dots with the amount of loaded protein and obtain a calibration line (R^2 values for calibration curves should be over 0.95).

3.13.4. Use the calibration curve to extrapolate the concentration of mRFP of each sample dot.

3.13.5. Calculate the concentration of the mRFP remaining in the unbound fractions.

NOTE: To ensure the correct closing of the dot blot apparatus and, therefore, to subject the membrane to a uniform pressure, tighten the screws by following a diagonally crossed scheme and, then, open the vacuum pump to tighten the screws more strongly.

4. Spore collection and reuse

4.1. For the recycling of the adsorbed spore, perform two adsorption reactions of 2.0×10^9 purified spores with 10 μ g of purified GH10-XA xylanase or 10 μ g of purified GH3-XT β -xylosidase, as described in steps 1.1–1.3 (**Figure 6A**).

4.2. Collect the pellets containing the enzyme-adsorbed spores, resuspend them in 50 μ L of the optimal buffer for the enzymatic reaction assay (50 mM sodium phosphate buffer at pH 6.5; 2.48689 g/L

Na₂HPO₄, 4.88991 g/L NaH₂PO₄), and mix them together to obtain a 100 µL mixture of spores adsorbing GH10-XA or GH3-XT.

4.3. Add the substrate (5 mg/mL 4-O-methyl-d-glucuronod-xylan [MGX]) and let the enzyme reactions take place for 16 h at 65 °C.

4.4. Centrifuge the reaction mixture (for 15 min at 13,000 x g) and store the supernatant containing the enzyme reaction product.

4.5. Resuspend the pellet in 100 µL of fresh 50 mM sodium phosphate buffer at pH 6.5 in the presence of a new substrate (MGX) (**Figure 6B**).

NOTE: To adsorb more than one enzyme, it is possible to adsorb both together or one by one independently. The latter possibility facilitates the quantitative analysis of the adsorption efficiency and of the activity of each enzyme, allowing a stoichiometric balance of each enzyme needed for the reactions.

REPRESENTATIVE RESULTS:

Successful adsorption can be assessed by western blotting. Upon the reaction, the mixture is fractionated by centrifugation and washed, and the pellet fraction (**Figure 1**) is used to extract the surface proteins. The extract is fractionated by SDS polyacrylamide gel electrophoresis (PAGE), electrotransferred to a polyvinylidene fluoride (PVDF) membrane, and reacted against primary and secondary antibodies. The presence of proteins of the expected size, only in the lane loaded with an extract of the adsorbed spores, is indicative of a successful adsorption reaction (**Figure 2A**).

The efficiency of the adsorption reaction can be evaluated by direct and indirect methods. The direct evaluation of the adsorption efficiency depends on the heterologous protein that has been used and can be performed by fluorescence microscopy (**Figure 2B**) and cytofluorimetry (**Figure 2C**) on the pellet fraction after the fractionation of the adsorption reaction. A quantification of the fluorescent signals present on spores can be performed by using the ImageJ software (**Figure 3** and **Figure 4**). An indirect analysis of the adsorption efficiency can be performed by a dot blotting analysis (**Figure 5A**) of the supernatant fraction containing the unbound protein (**Figure 1**). A densitometric analysis of the unbound protein (**Figure 5B**) will then allow scientists to calculate indirectly the amount of protein adsorbed on spores.

Two successive reactions can be catalyzed by a mixture of spores displaying either one of the two specific enzymes (**Figure 6A**). The adsorbed enzyme(s) can be collected with a simple centrifugation step, washed, and incubated with fresh substrate for a new reaction cycle (**Figure 6B**).

FIGURE LEGENDS:

Figure 1: General scheme of the adsorption experiment.

Figure 2: Direct analysis of the efficiency of the mRFP display. (A) Western blot with mRFP-specific antibody. C+ = free purified mRFP; C- = a protein extract from spores not adsorbed to the protein;

P2/P5/P10 = proteins extracted from *B. subtilis* spores adsorbed with 2, 5, and 10 mg of mRFP, respectively. (B) Immunofluorescence microscopy of adsorbed spores. Immunoreactions were performed with a primary antibody recognizing the adsorbed protein and with a fluorescent secondary antibody conjugated with fluorescein isothiocyanate (FITC). The left panel shows the red intrinsic mRFP fluorescence, the right panel shows the green fluorescence of FITC-conjugated secondary antibody. (C) Flow cytometric analysis of adsorbed spores. The spores reacted with mRFP-specific antibodies and with FITC-conjugated secondary antibodies and, then, were analyzed by cytofluorimetry. The analysis was performed on the entire spore population (10,000 events, ungated). In the left panel, not-adsorbed spores are shown in black, mRFP-adsorbed spores in red. The right panel shows the forward and side scatter (FSC-SSC) dot plot.

Figure 3: Manual quantification of the fluorescent signal by ImageJ. A fluorescence microscope image of spores, adsorbed with the red fluorescent protein mRFP, analyzed with ImageJ software. A yellow circle has been drawn around one spore to obtain densitometric data (enlarged image). The popup box shows the results of the densitometric analysis of the selected spore.

Figure 4: Simultaneous quantification of the fluorescent signal by ImageJ. (A) Popup box obtained when selecting **Analyze Particle**. An interval value of 50–200 pixel² has to be set for spores²³. (B) Segmentation of the image of **Figure 3A** after using **Analyze Particles** (left), and the relative densitometric analysis results (right).

Figure 5: Dot blotting and densitometric analysis. (A) Dot blotting with serial dilutions of the purified mRFP in duplicate (Std₁ and Std₂) and the supernatant (S10, S5, and S2) of the adsorption reaction performed with 10, 5, and 2 µg of mRFP, respectively²³. (B) The dot blotting of panel A is used for the densitometric analysis. The circles indicate the area used to quantitate the density of the signals. The panel on the right reports an example of results obtained with the densitometric analysis.

Figure 6: Conversion of xylan by reusable spores. (A) General scheme of xylan degradation. (B) Spores displaying the xylanase or the β-xylosidase enzymes, when mixed together, catalyze the two-step degradation of xylan. After the reaction, the sample is fractionated by centrifugation. The supernatant contains the reaction product, while the pellet contains spore-bound enzymes that can be reused by adding fresh substrate.

DISCUSSION:

This spore adsorption protocol is very simple and straightforward. The reaction is strictly dependent on the pH of the reaction buffer and the efficiency of adsorption is optimal at acidic pH values (pH 5.0 or lower). At neutral pH conditions, the efficiency of adsorption is low, and at alkaline pH values, adsorption may not occur. Optimal adsorption is obtained using a volume of 200 µL in 1.5 mL tubes (or keeping a similar ratio) on a rocking shaker.

Adsorption is very tight, and washes with a buffer at the same pH of the reaction buffer do not cause any release of the adsorbed proteins. Washes with alkaline buffers may result in a minimal (generally less than 15%²⁶) release of the adsorbed protein.

The indirect evaluation of the efficiency of adsorption by dot blotting is reliable if several dilutions of

purified and unbound protein are analyzed and the densitometric analysis is properly performed. No evidence of degradation of the heterologous proteins has been reported²⁵. The direct evaluation of the efficiency of adsorption greatly depends on the protein that is adsorbed. If the protein is autofluorescent or fluorescently labeled, an ImageJ-assisted analysis provides a quantitative determination of the fluorescence and of the amounts of fluorescent molecules present on the spore. If the protein has an enzymatic activity, a specific enzymatic assay could provide an indication of the amounts of protein present on the spores. However, it is known that the enzymatic activity associated with spores may be increased by a stabilization effect due to the interaction with the spore¹³. If the adsorbed protein is not fluorescent and does not have an enzymatic activity, the efficiency of adsorption can be evaluated by dot blotting on spores extracted under drastic conditions.

A collection of used spores can be done by a very simple procedure. A washing step with the reaction buffer may be important to remove reaction by-products, while the addition of fresh substrate is essential to initiate a new reaction²¹.

ACKNOWLEDGMENTS:

This work was supported by “Finanziamento di Ricerca di Ateneo” to L. Baccigalupi, project title “SP-LAY: Bacterial spores as live platform for proteins display”.

DISCLOSURES:

The authors have nothing to disclose.




REFERENCES:

1. Felici, F. et al. Peptide and protein display on the surface of filamentous bacteriophage. *Biotechnology Annual Review*. **1**, 149–183 (1995).
2. Cortese, R. et al. Identification of biologically active peptides using random libraries displayed on phage. *Current Opinion in Biotechnology*. **6**, 73–80 (1995).
3. Sousa, C., Cebolla, A., de Lorenzo, V. Enhanced metaladsorption of bacterial cells displaying poly-His peptides. *Nature Biotechnology*. **14**, 1017–1020 (1996).
4. Richins, R., Kaneva, I., Mulchandani, A., Chen, W. Biodegradation of organophosphorus pesticides by surface-expressed organophosphorus hydrolase. *Nature Biotechnology*. **15**, 984–987 (1997).
5. Wu, J.Y. et al. Expression of immunogenic epitopes of hepatitis B surface antigen with hybrid flagellin proteins by a vaccine strain of *Salmonella*. *Proceedings of the National Academy of Sciences of the United States of America*. **86**, 4726–4730 (1989).
6. Newton, S.M., Jacob, C.O., Stocker, B.A. Immune response to cholera toxin epitope inserted in *Salmonella* flagellin. *Science*. **244**, 70–72 (1989).
7. Fischetti, V.A., Medaglini, D., Pozzi, G. Gram-positive commensal bacteria for mucosal vaccine delivery. *Current Opinion in Biotechnology*. **7**, 659–666 (1996).
8. Isticato, R., Ricca, E. Spore surface display. *Microbiology Spectrum*. **2** (5), TBS-0011-2012, doi:10.1128/microbiolspec (2014).
9. Ricca, E. et al. Mucosal vaccine delivery by non-recombinant spores of *Bacillus subtilis*. *Microbial Cell Factories*. **13**, 115 (2014).
10. McKenney, P.T., Driks, A., Eichenberger, P. The *Bacillus subtilis* endospore: assembly and functions of the multilayered coat. *Nature Reviews Microbiology*. **11**, 33–44 (2013).

- 403 11. Knecht, L.D., Pasini, P., Daunert, S. Bacterial spores as platforms for bioanalytical and biomedical
404 applications. *Analytical and Bioanalytical Chemistry*. **400**, 977–989 (2011).
- 405 12. Isticato, R., Cangiano, G., De Felice, M., Ricca, E. Display of molecules on the spore surface. In
406 *Bacterial Spore Formers: Probiotics and Emerging Applications*. Edited by Ricca, E., Henriques, A.O.,
407 Cutting, S.M., 193–200, Horizon Biosciences. Norfolk, UK (2004).
- 408 13. Sirec, T. et al. Adsorption of β -galactosidase of *Alicyclobacillus acidocaldarius* on wild type and
409 mutant spores of *Bacillus subtilis*. *Microbial Cell Factories*. **11**, 100 (2012).
- 410 14. Cutting, S.M. *Bacillus* probiotics. *Food Microbiology*. **28**, 214–220 (2011).
- 411 15. Baccigalupi, L., Ricca, E., Ghelardi, E. Non-LAB Probiotics: Spore Formers. In *Probiotics and*
412 *Prebiotics: Current Research and Future Trends*. Edited by Venema, K., Do Carmo, A.P., 93–103, Caister
413 Academic Press (2014).
- 414 16. Cutting, S.M., Hong, H.A., Baccigalupi, L., Ricca, E. Oral Vaccine Delivery by Recombinant Spore
415 Probiotics. *International Reviews of Immunology*. **28**, 487–505 (2009).
- 416 17. Lee, S.Y., Choi, J.H., Xu, Z. Microbial cell-surface display. *Trends in Biotechnology*. **21**, 45–52 (2003).
- 417 18. Isticato, R. et al. Surface display of recombinant proteins on *Bacillus subtilis* spores. *Journal of*
418 *Bacteriology*. **183**, 6294–6301 (2001).
- 419 19. Huang, J.M. et al. Mucosal delivery of antigens using adsorption to bacterial spores. *Vaccine*. **28**,
420 1021–1030 (2010).
- 421 20. Isticato, R. et al. Non-recombinant display of the B subunit of the heat labile toxin of *Escherichia coli*
422 on wild type and mutant spores of *Bacillus subtilis*. *Microbial Cell Factories*. **12**, 98 (2013).
- 423 21. Mattosovich, R. et al. Conversion of xylan by recyclable spores of *Bacillus subtilis* displaying
424 thermophilic enzymes. *Microbial Cell Factories*. **16**, 218 (2017).
- 425 22. Pesce, G. et al. Surface charge and hydrodynamic coefficient measurements of *Bacillus subtilis* spore
426 by optical tweezers. *Colloids and Surfaces B: Biointerfaces*. **116C**, 568–575 (2014).
- 427 23. Donadio, G. et al. Localization of a red fluorescence protein adsorbed on wild type and mutant
428 spores of *Bacillus subtilis*. *Microbial Cell Factories*. **15**, 153 (2016).
- 429 24. Pan, J.G., Choi, S.K., Jung, H.C., Kim, E.J. Display of native proteins on *Bacillus subtilis* spores. *FEMS*
430 *Microbiology Letters*. **358**, 209–217 (2014).
- 431 25. Cutting, S., Vander Horn, P.B. Genetic analysis. In *Molecular Biological Methods for Bacillus*. Edited
432 by Harwood, C., Cutting, S., John Wiley & Sons. Chichester, UK (1990).
- 433 26. Lanzilli, M. et al. Display of the peroxiredoxin Bcp1 of *Sulfolobus solfataricus* on probiotic spores of
434 *Bacillus megaterium*. *New Biotechnology*. **46**, 38 (2018).

spores
(2.0×10^9)




purified heterologous protein (2, 5, 10 μ g)



25 °C/1 hour/shaking
Acid pH



Centrifugation



*Bound fraction
(pellet)*

*Unbound fraction
(supernatant)*

Direct analysis
of the display
efficiency

Indirect analysis
of the display
efficiency

Direct analysis of the display efficiency:






Figure 3

[Click here to access/download;Figure;figure 3 jove.png](#)




Figure 4

[Click here to access/download;Figure;figure 4 jove.png](#)






Figure 5

A




B




Index	Name	Concentration	Quantity	Vol. for
		mg	mg/ml	mg/ml
1	Std1	200.00	10.00	2.00
2	Std2	100.00	5.00	1.00
3	S10	50.00	2.50	0.50
4	S5	25.00	1.25	0.25
5	S2	12.50	0.625	0.125
6	Std3	6.25	0.3125	0.0625
7	U1	10.00	0.50	0.10
8	U2	10.00	0.50	0.10
9	U3	10.00	0.50	0.10
10	U4	10.00	0.50	0.10
11	U5	10.00	0.50	0.10
12	U6	10.00	0.50	0.10

Figure 6

A



B



Name of Material/ Equipment	Company	Catalog Number
0.1% Poly-L-lysine solution	Sigma	P8920
0.45 µm Nitrocellulose Blotting	Sartorius	M_Blotting_Membranes
100× objective UPlanF1	Olympus	microscope equipment
Bacillus subtilis strain NCIB3610	Bacillus Genetic Stock	3A1
BD ACCURI C6 PLUS	BD	flow cytometer
BX51	Olympus	Fluorescent microscope
Clarity	Biorad	1705060
DP70 digital camera a	Olympus	microscope equipment
Goat anti-Rabbit IgG (H+L) Cross-Adsorbed Secondary Antibody, FITC	Thermo fisher	F-2754
Goat Anti-Rabbit IgG H&L (HRP)	Abcam	ab6721
Monoclonal Anti-polyHistidine–Peroxidase antibody	Sigma	A7058-1VL
SecureSlip glass coverslip	Sigma	S1815-1PAK
Superwhite Uncharged Microscope Slides	VWR	75836-190
U-CA Magnification Changer	Olympus	microscope equipment

Comments/Description

used to detect adsorbed proteins presenting a
6xhistidine-tag at C- or N- terminal



1 Alewife Center #200
Cambridge, MA 02140
tel. 617.945.9051
www.jove.com

ARTICLE AND VIDEO LICENSE AGREEMENT

Title of Article:

Spore adsorption: a non-recombinant display system

Author(s):

Rachele Isticato, Ezio Ricca, Loredana Baccigalupi

Item 1 (check one box): The Author elects to have the Materials be made available (as described at

<http://www.jove.com/author>) via: ☒ Standard Access ☐ Open Access

Item 2 (check one box):



The Author is NOT a United States government employee.



The Author is a United States government employee and the Materials were prepared in the course of his or her duties as a United States government employee.



The Author is a United States government employee but the Materials were NOT prepared in the course of his or her duties as a United States government employee.

ARTICLE AND VIDEO LICENSE AGREEMENT

1. Defined Terms. As used in this Article and Video License Agreement, the following terms shall have the following meanings: “**Agreement**” means this Article and Video License Agreement; “**Article**” means the article specified on the last page of this Agreement, including any associated materials such as texts, figures, tables, artwork, abstracts, or summaries contained therein; “**Author**” means the author who is a signatory to this Agreement; “**Collective Work**” means a work, such as a periodical issue, anthology or encyclopedia, in which the Materials in their entirety in unmodified form, along with a number of other contributions, constituting separate and independent works in themselves, are assembled into a collective whole; “**CRC License**” means the Creative Commons Attribution-Non Commercial-No Derivs 3.0 Unported Agreement, the terms and conditions of which can be found at: <http://creativecommons.org/licenses/by-nc-nd/3.0/legalcode>; “**Derivative Work**” means a work based upon the Materials or upon the Materials and other pre-existing works, such as a translation, musical arrangement, dramatization, fictionalization, motion picture version, sound recording, art reproduction, abridgment, condensation, or any other form in which the Materials may be recast, transformed, or adapted; “**Institution**” means the institution, listed on the last page of this Agreement, by which the Author was employed at the time of the creation of the Materials; “**JoVE**” means MyJoVE Corporation, a Massachusetts corporation and the publisher of *The Journal of Visualized Experiments*; “**Materials**” means the Article and / or the Video; “**Parties**” means the Author and JoVE; “**Video**” means any video(s) made by the Author, alone or in conjunction with any other parties, or by JoVE or its affiliates or agents, individually or in collaboration with the Author or any other parties, incorporating all or any portion of the Article, and in which the Author may or may not appear.

2. Background. The Author, who is the author of the Article, in order to ensure the dissemination and protection of the Article, desires to have the JoVE publish the Article and create and transmit videos based on the Article. In furtherance of such goals, the Parties desire to memorialize in this Agreement the respective rights of each Party in and to the Article and the Video.

3. Grant of Rights in Article. In consideration of JoVE agreeing to publish the Article, the Author hereby grants to JoVE, subject to **Sections 4** and **7** below, the exclusive, royalty-free, perpetual (for the full term of copyright in the Article, including any extensions thereto) license (a) to publish, reproduce, distribute, display and store the Article in all forms, formats and media whether now known or hereafter developed (including without limitation in print, digital and electronic form) throughout the world, (b) to translate the Article into other languages, create adaptations, summaries or extracts of the Article or other Derivative Works (including, without limitation, the Video) or Collective Works based on all or any portion of the Article and exercise all of the rights set forth in (a) above in such translations, adaptations, summaries, extracts, Derivative Works or Collective Works and (c) to license others to do any or all of the above. The foregoing rights may be exercised in all media and formats, whether now known or hereafter devised, and include the right to make such modifications as are technically necessary to exercise the rights in other media and formats. If the “Open Access” box has been checked in **Item 1** above, JoVE and the Author hereby grant to the public all such rights in the Article as provided in, but subject to all limitations and requirements set forth in, the CRC License.

ARTICLE AND VIDEO LICENSE AGREEMENT

4. Retention of Rights in Article. Notwithstanding the exclusive license granted to JoVE in **Section 3** above, the Author shall, with respect to the Article, retain the non-exclusive right to use all or part of the Article for the non-commercial purpose of giving lectures, presentations or teaching classes, and to post a copy of the Article on the Institution's website or the Author's personal website, in each case provided that a link to the Article on the JoVE website is provided and notice of JoVE's copyright in the Article is included. All non-copyright intellectual property rights in and to the Article, such as patent rights, shall remain with the Author.

5. Grant of Rights in Video – Standard Access. This **Section 5** applies if the "Standard Access" box has been checked in **Item 1** above or if no box has been checked in **Item 1** above. In consideration of JoVE agreeing to produce, display or otherwise assist with the Video, the Author hereby acknowledges and agrees that, Subject to **Section 7** below, JoVE is and shall be the sole and exclusive owner of all rights of any nature, including, without limitation, all copyrights, in and to the Video. To the extent that, by law, the Author is deemed, now or at any time in the future, to have any rights of any nature in or to the Video, the Author hereby disclaims all such rights and transfers all such rights to JoVE.

6. Grant of Rights in Video – Open Access. This **Section 6** applies only if the "Open Access" box has been checked in **Item 1** above. In consideration of JoVE agreeing to produce, display or otherwise assist with the Video, the Author hereby grants to JoVE, subject to **Section 7** below, the exclusive, royalty-free, perpetual (for the full term of copyright in the Article, including any extensions thereto) license (a) to publish, reproduce, distribute, display and store the Video in all forms, formats and media whether now known or hereafter developed (including without limitation in print, digital and electronic form) throughout the world, (b) to translate the Video into other languages, create adaptations, summaries or extracts of the Video or other Derivative Works or Collective Works based on all or any portion of the Video and exercise all of the rights set forth in (a) above in such translations, adaptations, summaries, extracts, Derivative Works or Collective Works and (c) to license others to do any or all of the above. The foregoing rights may be exercised in all media and formats, whether now known or hereafter devised, and include the right to make such modifications as are technically necessary to exercise the rights in other media and formats. For any Video to which this Section 6 is applicable, JoVE and the Author hereby grant to the public all such rights in the Video as provided in, but subject to all limitations and requirements set forth in, the CRC License.

7. Government Employees. If the Author is a United States government employee and the Article was prepared in the course of his or her duties as a United States government employee, as indicated in **Item 2** above, and any of the licenses or grants granted by the Author hereunder exceed the scope of the 17 U.S.C. 403, then the rights granted hereunder shall be limited to the maximum rights permitted under such

statute. In such case, all provisions contained herein that are not in conflict with such statute shall remain in full force and effect, and all provisions contained herein that do so conflict shall be deemed to be amended so as to provide to JoVE the maximum rights permissible within such statute.

8. Likeness, Privacy, Personality. The Author hereby grants JoVE the right to use the Author's name, voice, likeness, picture, photograph, image, biography and performance in any way, commercial or otherwise, in connection with the Materials and the sale, promotion and distribution thereof. The Author hereby waives any and all rights he or she may have, relating to his or her appearance in the Video or otherwise relating to the Materials, under all applicable privacy, likeness, personality or similar laws.

9. Author Warranties. The Author represents and warrants that the Article is original, that it has not been published, that the copyright interest is owned by the Author (or, if more than one author is listed at the beginning of this Agreement, by such authors collectively) and has not been assigned, licensed, or otherwise transferred to any other party. The Author represents and warrants that the author(s) listed at the top of this Agreement are the only authors of the Materials. If more than one author is listed at the top of this Agreement and if any such author has not entered into a separate Article and Video License Agreement with JoVE relating to the Materials, the Author represents and warrants that the Author has been authorized by each of the other such authors to execute this Agreement on his or her behalf and to bind him or her with respect to the terms of this Agreement as if each of them had been a party hereto as an Author. The Author warrants that the use, reproduction, distribution, public or private performance or display, and/or modification of all or any portion of the Materials does not and will not violate, infringe and/or misappropriate the patent, trademark, intellectual property or other rights of any third party. The Author represents and warrants that it has and will continue to comply with all government, institutional and other regulations, including, without limitation all institutional, laboratory, hospital, ethical, human and animal treatment, privacy, and all other rules, regulations, laws, procedures or guidelines, applicable to the Materials, and that all research involving human and animal subjects has been approved by the Author's relevant institutional review board.

10. JoVE Discretion. If the Author requests the assistance of JoVE in producing the Video in the Author's facility, the Author shall ensure that the presence of JoVE employees, agents or independent contractors is in accordance with the relevant regulations of the Author's institution. If more than one author is listed at the beginning of this Agreement, JoVE may, in its sole discretion, elect not take any action with respect to the Article until such time as it has received complete, executed Article and Video License Agreements from each such author. JoVE reserves the right, in its absolute and sole discretion and without giving any reason therefore, to accept or decline any work submitted to JoVE. JoVE and its employees, agents and independent contractors shall have

ARTICLE AND VIDEO LICENSE AGREEMENT

full, unfettered access to the facilities of the Author or of the Author's institution as necessary to make the Video, whether actually published or not. JoVE has sole discretion as to the method of making and publishing the Materials, including, without limitation, to all decisions regarding editing, lighting, filming, timing of publication, if any, length, quality, content and the like.

11. **Indemnification.** The Author agrees to indemnify JoVE and/or its successors and assigns from and against any and all claims, costs, and expenses, including attorney's fees, arising out of any breach of any warranty or other representations contained herein. The Author further agrees to indemnify and hold harmless JoVE from and against any and all claims, costs, and expenses, including attorney's fees, resulting from the breach by the Author of any representation or warranty contained herein or from allegations or instances of violation of intellectual property rights, damage to the Author's or the Author's institution's facilities, fraud, libel, defamation, research, equipment, experiments, property damage, personal injury, violations of institutional, laboratory, hospital, ethical, human and animal treatment, privacy or other rules, regulations, laws, procedures or guidelines, liabilities and other losses or damages related in any way to the submission of work to JoVE, making of videos by JoVE, or publication in JoVE or elsewhere by JoVE. The Author shall be responsible for, and shall hold JoVE harmless from, damages caused by lack of sterilization, lack of cleanliness or by contamination due to the making of a video by JoVE its employees, agents or independent contractors. All sterilization, cleanliness or decontamination procedures shall be solely the responsibility of the Author and shall be undertaken at the Author's

expense. All indemnifications provided herein shall include JoVE's attorney's fees and costs related to said losses or damages. Such indemnification and holding harmless shall include such losses or damages incurred by, or in connection with, acts or omissions of JoVE, its employees, agents or independent contractors.


12. **Fees.** To cover the cost incurred for publication, JoVE must receive payment before production and publication the Materials. Payment is due in 21 days of invoice. Should the Materials not be published due to an editorial or production decision, these funds will be returned to the Author. Withdrawal by the Author of any submitted Materials after final peer review approval will result in a US\$1,200 fee to cover pre-production expenses incurred by JoVE. If payment is not received by the completion of filming, production and publication of the Materials will be suspended until payment is received.

13. **Transfer, Governing Law.** This Agreement may be assigned by JoVE and shall inure to the benefits of any of JoVE's successors and assignees. This Agreement shall be governed and construed by the internal laws of the Commonwealth of Massachusetts without giving effect to any conflict of law provision thereunder. This Agreement may be executed in counterparts, each of which shall be deemed an original, but all of which together shall be deemed to be one and the same agreement. A signed copy of this Agreement delivered by facsimile, e-mail or other means of electronic transmission shall be deemed to have the same legal effect as delivery of an original signed copy of this Agreement.

Testo

A signed copy of this document must be sent with all new submissions. Only one Agreement required per submission.

CORRESPONDING AUTHOR:

Name:	Ezio Ricca	
Department:	Department of Biology	
Institution:	Federico II University of Naples	
Article Title:	Spore adsorption: a non-recombinant display system	
Signature:		Date: 09/13/2018

Please submit a signed and dated copy of this license by one of the following three methods:

- 1) Upload a scanned copy of the document as a pdf on the JoVE submission site;
- 2) Fax the document to +1.866.381.2236;
- 3) Mail the document to JoVE / Attn: JoVE Editorial / 1 Alewife Center #200 / Cambridge, MA 02139

For questions, please email submissions@jove.com or call +1.617.945.9051

Dear Dr. Ricca,

Your manuscript, JoVE59102 "Spore adsorption: a non-recombinant display system," has been editorially and peer reviewed, and the following comments need to be addressed. Note that editorial comments address both requirements for video production and formatting of the article for publication. Please track the changes within the manuscript to identify all of the edits.

After revising and uploading your submission, please also upload a separate rebuttal document that addresses each of the editorial and peer review comments individually. Please submit each figure as a vector image file to ensure high resolution throughout production: (.svg, .eps, .ai). If submitting as a .tif or .psd, please ensure that the image is 1920 x 1080 pixels or 300 dpi.

Your revision is due by **Oct 24, 2018**.

To submit a revision, go to the [JoVE submission site](#) and log in as an author. You will find your submission under the heading "Submission Needing Revision".

Best,

Peer Review,

Peer Review

[JoVE](#)

617.674.1888

Follow us: [Facebook](#) | [Twitter](#) | [LinkedIn](#)

[About JoVE](#)

Editorial comments:

Changes to be made by the author(s) regarding the written manuscript:

1. Please take this opportunity to thoroughly proofread the manuscript to ensure that there are no spelling or grammar issues.

2. Please revise lines 32-34, 74-77, 94-95, 170-171, 200-202 to avoid previously published text.

The lines have been changed with the sentences in red

3. Please revise the title to avoid punctuation and to represent the content included in the protocol.

we changed the title following also the suggestion of reviewer 4

4. Please define all abbreviations before use. **Done**

5. Please adjust the numbering of the Protocol to follow the JoVE Instructions for Authors. For example, 1 should be followed by 1.1 and then 1.1.1 and 1.1.2 if necessary. Please refrain from using bullets, dashes, or indentations.

Done

6. Please revise the protocol text to avoid the use of any personal pronouns (e.g., "we", "you", "our" etc.). **Done**

7. Please add more details to your protocol steps. There should be enough detail in each step to supplement the actions seen in the video so that viewers can easily replicate the protocol. Please ensure you answer the "how" question, i.e., how is the step performed? Alternatively, add references to published material specifying how to perform the protocol action. See examples below:

Line 107: Please specify the proteins that will be used in the video and specify incubation temperature. **Done**

Line 115: Please provide the composition of binding buffer. Is it the same as acid buffer? What volume of buffer is used to wash? **Done**

Line 123: Please specify the centrifugation parameters (force and time) and antibodies used. **Done**

Line 192: Please describe how this step is actually performed. **Done**

Lines 239-251: We cannot film a generalized protocol; we need specific details of a specific experiment. For instance, please specify the enzymes, optimal buffer, enzyme reaction conditions used in these steps. **Done**

Line 251: Please specify the fresh buffer and new substrate added. **Done**

8. Please combine some of the shorter Protocol steps so that individual steps contain 2-3 actions and maximum of 4 sentences per step. **Done**

9. Please include single-line space s between all paragraphs, headings, steps, etc. **Done**

10. After you have made all the recommended changes to your protocol (listed above), please highlight 2.75 pages or less of the Protocol (including headings and spacing) that identifies the essential steps of the protocol for the video, i.e., the steps that should be visualized to tell the most cohesive story of the Protocol

Done

11. Please highlight complete sentences (not parts of sentences). Please ensure that the highlighted part of the step includes at least one action that is written in imperative tense

Done

12. Please include all relevant details that are required to perform the step in the highlighting. For example: If step 2.5 is highlighted for filming and the details of how to perform the step are given in steps 2.5.1 and 2.5.2, then the sub-steps where the details are provided must be highlighted.

Done

13. Are any figures reprinted from previous publications? If yes, please obtain explicit copyright permission to reuse any figures from a previous publication. Explicit permission can be expressed in the form of a letter from the editor or a link to the editorial policy that allows re-prints. Please upload this information as a .doc or .docx file to your Editorial Manager account. The Figure must be cited appropriately in the Figure Legend, i.e. "This figure has been modified from [citation]."

The figures are original and never published before

14. Figure 3: The yellow circle can hardly be seen. Please revise to make it more visible.

The images of figure 3 are from ImageJ software, and the yellow circle comes automatically from the program. We have now added a hard yellow circle to the original one to make it more visible.

15. Discussion: As we are a methods journal, please also discuss critical steps within the protocol, any modifications and troubleshooting of the technique, and any limitations of the technique.

Other comments have been added in the discussion (lines 334-335 and 337-338)

16. References: Please do not abbreviate journal titles.

References have been corrected

Reviewers' comments:

Reviewer #1:

Manuscript Summary:

This is a nice description of use of bacterial spores to adsorb proteins, to assess the levels of adsorbed proteins, and then use of these spores with adsorbed proteins.

Major Concerns:

The English usage needs much work, as there are many examples of use of inappropriate words or grammar. However, the meaning of everything is clear. Three examples in the summary are: 1) line 21 change "expose" to "adsorb"; 2) line 22, change "activity" to "activities"; and line 23 - change "have been shown" to "are also."

Done

Minor Concerns:

1) line 53 and elsewhere - I am not sure that they spore structure is "peculiar" - perhaps "novel" is a better word. **The spore is a "peculiar" cell form due to its quiescent metabolism, its dehydrated cytoplasm and surrounding layers.**

2) line 96 and elsewhere - make it clear that it is the spores with adsorbed enzymes that are not recovered, not the enzymes themselves.

The Introduction has been modified clarifying this point.

3) lines 123-126 - what about analyzing the supernatant from step 4 in the Adsorption reaction? **This is the analysis described at point 4 and named "indirect evaluation of the efficiency of adsorption". A sentence has been added at lines 112-113 to clarify this point.**

4) lines 139, 143 - define DIC and FACS - and other abbreviations as well.

Done

5) line 187 - which supernatant?

The point has been clarified (lines 194-195)

6) line 192 - perhaps say something here about the "membrane".

Done

7) line 195 and elsewhere - "Dot blot apparatus", not "Dot apparatus".

Done

8) line 225 - software such as ImageJ?

two examples of possible software have been reported.

9) line 243 - if the pH must be maintained at ~4.0 to keep proteins adsorbed, how does this influence enzyme activity assays?

when possible, it is recommended to perform the enzymatic reaction at a pH lower than the isoelectric point of the adsorbed enzyme. If not possible, a bit release of the adsorbed protein

could occur (less than 15%, ref 26). A comment about this point has been added in the discussion (lines 337-338)

10) line 273 - spore-free supernatant, not cell-free.

Corrected

11) Legends to Fig 2-5, make clear that *B. subtilis* spores (I presume) are used in these experiments.

We have specified in the text that spores of *Bacillus subtilis* have been used in the described protocols.

12) Fig 2 legend - what is the fluorescent protein in panel B, and the enzyme in panel C? If the assay is at pH 7, do most protein deadsorb? Would this preclude reuse of these spores?

Figure 2 has been modified and now it reports the results obtained with the adsorption of the monomeric red fluorescent protein mRFP on the *B. subtilis* spores. Also the text (paragraph "representative results") has been corrected

13) line 289 and elsewhere - fluorescent here should be "fluorescence".

Corrected

14) line 310 - recycled should be reused - any data on what % of adsorbed protein is lost after one use of the spores, especially if for a reaction at pH 7?

A sentence about the loss of product in the second reaction has been added in the introduction (lines 88-90)

15) References 12 and 13 - titles of articles are in all capitals.

Done.

16) Fig. 3 - I am not sure that panel B is needed - these numbers could be added to the inset in panel A. Perhaps note in text about the inset in panel A, that the adsorbed protein is in spores' outer layers.

Done

17) Fig. 5 - in panel B, "Surnatant" should be "Supernatant".

Done

18) Table - some of the names of material/Equipment have been cut off I presume the Superwhite uncharged microscope should be followed by slides, and something is also missing after "blotting".

Corrected

Reviewer #2:

Manuscript Summary:

The authors present several broadly-applicable protocols for adsorbing proteins onto *Bacillus* spores and characterising 'loaded' spores. The protocols are straightforward and clearly described, and would be of use to researchers who would like to try this approach for the first time. The MS does require copy-editing for language issues particularly in the protocol section itself.

Major Concerns:

Some references in the introduction are quite dated, especially in regard to spores as vaccine

delivery vehicles. Recent references include: Copland et al Front Immunol. 2018 Mar 12;9:346., Zhou et al J Med Microbiol. 2017 Jan;66(1):83-89., Sun H et al Parasit Vectors. 2018 Mar 7;11(1):156.

The original paper (ref. 18) and recent reviews (ref. 8 and 9) on the spore systems have been cited. The suggested references describe specific examples of spore display and we believe are not appropriate.

Emphasis is placed on the use of spores as a molecular display system akin to phage display. This can be achieved using recombinant spores but it is less clear how this would work with the in vitro adsorption techniques described here. This should be clarified.

The Introduction has been modified and it has been clarified that the non-recombinant spore display is proposed as a delivery system and not to replace phages in the screening of peptide libraries.

Although preparation of the spores is outside of the scope of these protocols, some specification of the spores used here would be helpful to allow researchers to gauge the appropriateness of the protocols for their particular application. For example, is this suitable for spores that have been autoclave sterilised, or those from all *Bacillus* species?

In the text (line 107) we specified that *Bacillus subtilis* spores are used in the described experiments and that autoclaved spores can also be used (lines 78-80).

Minor Concerns:

The software used for densitometric analysis should be stated. Is there appropriate open-source or freely available software that could be recommended?

Examples of open-source and freely available software have been added in the text.

Figure 2A - lane labels are misaligned.

Corrected

A cytometry dot plot of physical characteristics of the spores (FSC/SSC) and any recommended gating approaches would add to Figure 2B

The graphs of figure 2C (in the new version of figure 2) were obtained analyzing the entire spore population (10,000 events, ungated) and were intended to be only an example of the methodology.

Figure resolution is poor throughout review pdf

The resolution has been increased

l240 - 'paragraph 1' should read 'protocol 1'

Done

Reviewer #3:

Manuscript Summary:

The technical quality is fair. This topic and experimental protocol could be very interesting for readers working in the specific field. The manuscript can be acceptable for publication in JoVE. However, in its present form there are some parts to be supplemented or revised.

Major Concerns:

1. A recent study entitled "Display of native proteins on Bacillus subtilis spores" described a method of native protein display on the Bacillus spore surface that obviates the need to construct fusion proteins to display a motif. Does this display system be classified as recombinant or non-recombinant display system? In my opinion, It is necessary to add comments on this display system in the manuscript.

A comment has been added to clarify the point (lines 92-99).

2. The introduction may be shortened to the information most relevant to the work.

Done

3. All micrographs in figures 2B, 3 & 4 are of poor quality. New and improved micrographs are required. The micrographs have been replaced.

Minor Concerns:

1. Line 115: Is the binding buffer same as an acid buffer(line 107)? If not, please provide the recipe for binding buffer. The binding buffer is the acid buffer used in the adsorption reaction, as clarified in the text (lines 112-115)

2. Line 131: Replace "slides" by "slide".

Done

3. Line 137: The first letter of "Fluorescent" written in lowercase.

Done

4. Line 321-323: Please provide references for the following statement "with small proteins or peptides adsorbed more efficiently than large".

The sentence has been deleted.

5. Line 333: What does "ad hoc" mean? Please describe in more detail

The word "ad hoc" has been replaced with "specific" (line 345)

6. In section "Adsorption reaction": some details is lost. For example, "in a shaker bath": how many is rotation rate? ; "Wash the pellet with the binding buffer": how many the volume?

More details have been added in the text

7. In figure 5: How to determine the adsorbed protein molecules per spore. A detailed calculation procedure would be helpful to illustrate the adsorption efficiency.

The amount of adsorbed protein is indirectly calculated determining by dot-blot the amount of unbound protein. We added the indication of the calibration curve to extrapolate the concentration of heterologous protein in each sample dots and calculate the average of the significative values (line 239)

8. References list:

Reference should be given in a reference list according to the Journal's style. So writing style of

references must be checked again.

Line 383-384: please check the article and journal name. **Done**

Line 392, 395, 397, 400, 406: the journal name is not abbreviated. **Done**

Reviewer #4:

Manuscript Summary:

The manuscript is well written and describes in detail protocols for adsorption and recycling of *B. subtilis* spores as a platform for adsorption of enzymes and antigens without the need to generate genetically modified strains. The protocol will find interest for those interested in the use of the platform as an alternative for the display of proteins for different purposes.

Major Concerns:

No major concern.

Minor Concerns:

Alternative title: "Spore adsorption: a non-recombinant display system for enzymes and antigens"
the title has been changed